Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Prada, Pedro J ^a   Mendez, Lucia ^a   Fernández, José ^a   González, Herminio ^a   Jiménez, Isabel ^a   Arrojo, Elisabeth ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; TUMOR LOCALIZATION; URETHRA STRICTURE; URETHRITIS; URINARY FREQUENCY; URINARY TRACT PAIN; URINE RETENTION; UROGENITAL TRACT DISEASE; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; GASTROINTESTINAL DISEASE; MICTURITION DISORDER; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR; RADIATION INJURY;

AGED; BRACHYTHERAPY; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; URINATION DISORDERS;

EID: 84857753531     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-31     Document Type: Article

References (35)

1. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993, 41:113-120. 10.1016/0090-4295(93)90159-8, 7684543.
2. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997, 32:385-390.
3. Hanks GE, Diamond JJ, Kual JM, et al. 17 ten-year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987, 13(4):499-505. 10.1016/0360-3016(87)90063-0, 3558040.
4. Pollack A, Zagars GK. External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 39(5):1011-1018. 10.1016/S0360-3016(97)00508-7, 9392538.
5. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J Clin Oncol 2000, 18(23):3904-3911.
6. Hanks EG, Hanlon AL, Pinover WH, et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiot Oncol Biol Phys 2000, 46(4):823-832.
7. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local of prostate cancer. Int J Radiat Oncol Biol Phys 1988, 15(6):1299-1305. 10.1016/0360-3016(88)90224-6, 3198435.
8. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show a high sensitivity to fractionation (low α/β), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13. 10.1016/S0360-3016(01)02664-5, 11777617.
9. American Joint Committee on cancer Prostate. AJCC Cancer Staging Manual 1992, 181-186. Philadelphia: Lippincott-Raven, Beahrs OH, Henson DE, Htter RVP, Kennedy BJ, 4, American Joint Committee on cancer.
10. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500. 10.1016/S0360-3016(98)00091-1, 9635694.
11. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal Therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
12. Cox DR. Regression models and life-tables. J R Stat Soc B 1972, 34:187-220.
13. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054, 17765406.
14. Zelefsky MJ, Fuks Z, Hunt M, et al. Margie Hunt et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urology 2001, 166:876-881.
15. Hanks GE, Hanlon AL, Pinover WH, et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000, 46(4):823-832. 10.1016/S0360-3016(99)00498-8, 10705002.
16. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92:488-498. 2362084, 15685244.
17. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199. 10.1200/JCO.2005.06.154, 15718316.
18. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239. 10.1001/jama.294.10.1233, 16160131.
19. Martinez A, Gonzalez J, Spencer W, et al. Conformal High dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urology 2003, 169:974-980.
20. Galalae RM, Kovács G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using High-dose- rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52:81-90. 10.1016/S0360-3016(01)01758-8, 11777625.
21. Dattoli M, Wallner K, True L, et al. Long-term outcome after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007, 110(3):551-555. 10.1002/cncr.22810, 17577217.
22. Mate TP, Gottesman JE, Hatton J, et al. High dose-rate after loading 192 iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533. 10.1016/S0360-3016(98)00097-2, 9635698.
23. Stock RG, Cesareti JA, Hall SJ, Stone NN. Outcome for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009, 104:1631-1636. 10.1111/j.1464-410X.2009.08661.x, 19493260.
24. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J Urol 2004, 172:910-914. 10.1097/01.ju.0000134888.22332.bb, 15310996.
25. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523. 10.1016/S0022-5347(05)63946-8, 12544300.
26. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins Experience after 10 years. Urol Clin N Am 1993, 20:713-725.
27. Kernen KM, Miles BJ. Prostate cancer treatment outcomes after radical prostatectomy: The Baylor experience (Abstr). Radiother Oncol 2000, 55(Suppl 1):7-8.
28. Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010, 107:765-770.
29. Ficarra V, Novara G, Artibani W, et al. Retropubic laparoscopy, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009, 55:1037-1063. 10.1016/j.eururo.2009.01.036, 19185977.
30. Merrick GS, Butler WM, Galbreath RW, et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk features?. BJU Int 2003, 91(1):23-29. 10.1046/j.1464-410X.2003.04024.x, 12614244.
31. Martinez A, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol 2003, 170(6):2296-2301. 10.1097/01.ju.0000096709.05800.48, 14634400.
32. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002, 360:103-106. 10.1016/S0140-6736(02)09408-4, 12126818.
33. Denham JW, Steigler A, Lamb DS, et al. Shortterm androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 2005, 6(11):841-850. 10.1016/S1470-2045(05)70348-X, 16257791.
34. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61(5):1285-1290. 10.1016/j.ijrobp.2004.08.047, 15817329.
35. Prada PJ, Fernández J, Martínez A, et al. Transperineal injection of hyaluronic acid in the anterior peri-rectal fat to decease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69(1):95-102. 10.1016/j.ijrobp.2007.02.034, 17707267.